Affinage

IGF2BP1

Insulin-like growth factor 2 mRNA-binding protein 1 · UniProt Q9NZI8

Length
577 aa
Mass
63.5 kDa
Annotated
2026-06-10
100 papers in source corpus 37 papers cited in narrative 35 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IGF2BP1 is an oncofetal m6A-reader RNA-binding protein that post-transcriptionally controls the fate of target mRNAs to govern cell migration, proliferation, stemness, and tissue development (PMID:30371874, PMID:29660014, PMID:36067310). Its dominant mechanism is m6A-dependent recognition of target transcripts, where binding stabilizes mRNAs by antagonizing miRNA/RISC-directed decay; IGF2BP1 associates with target mRNAs in RISC-free complexes, and its loss enhances AGO2 association and degradation of targets such as SRF (PMID:30371874, PMID:29660014). Stabilization is reinforced by recruitment of co-factors including PABPC1 to m6A 3'UTR sites (PMID:33391523), and it acts on an extensive target set spanning oncogenic and barrier programs — PTEN and MAPK4 to enforce directional migration via actin dynamics (PMID:22279049), cIAP1 to suppress apoptosis (PMID:24704827), PD-L1 to drive immune evasion (PMID:38029830), EZH2 to silence cell-cycle genes (PMID:35565249), and occludin to maintain intestinal tight junctions (PMID:32385106). In neurons IGF2BP1 localizes β-actin mRNA for transport and anchoring to support cortical development and axon outgrowth (PMID:36067310, PMID:26325373). Its activity and abundance are tuned by a network of post-translational modifications: PRMT3-mediated arginine methylation at R452 (PMID:37024475), mTORC2 Ser181 and Src Tyr396 phosphorylation (PMID:33388443), ZDHHC1 palmitoylation at C337 (PMID:39069526), and competing ubiquitination by FBXO45 (K190/K450, activating) and TRIM29 (K48-linked K440/K450, degrading) opposed by USP10 deubiquitination (PMID:34779401, PMID:38029830, PMID:36632454). The protein is functionally co-opted by regulatory lncRNAs and oncopeptides (RBRP, Lnc-THOR, MNX1-AS1) that enhance its m6A recognition or drive its phase separation (PMID:32245947, PMID:30503558, PMID:36214649), and its RNA-binding KH3-4 interface and KH1-2 Cys253 are targetable by small molecules that block recognition of KRAS and c-MYC mRNAs (PMID:36032766, PMID:34895045).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2012 High

    Established that IGF2BP1 directs cell migration through dual post-transcriptional control of cytoskeletal signaling, defining a concrete mechanistic cascade rather than a generic RNA-binding role.

    Evidence RNA binding, knockdown/overexpression, migration assays, and epistasis with MK5/RAC1/HSP27 in tumor cell lines

    PMID:22279049

    Open questions at the time
    • Did not address m6A dependence of these specific targets
    • Did not establish in vivo relevance
  2. 2014 Medium

    Showed IGF2BP1 enforces apoptosis resistance by driving cIAP1 translation, linking its activity to tumor cell survival under death-receptor stress.

    Evidence Knockdown, cIAP1 protein/mRNA quantification, TNF-α apoptosis assays, in vivo tumor growth with IAP antagonists

    PMID:24704827

    Open questions at the time
    • Mechanism of translational enhancement not resolved
    • m6A involvement not tested
  3. 2017 Medium

    Demonstrated IGF2BP1 can reprogram differentiated cells toward a fetal state by post-transcriptionally repressing BCL11A, extending its oncofetal role to erythroid identity.

    Evidence Erythroid-specific overexpression, HPLC hemoglobin quantification, polysome and mRNA stability assays in primary human erythroblasts

    PMID:28652347

    Open questions at the time
    • Direct binding to BCL11A mRNA not fully resolved
    • m6A dependence not addressed
  4. 2019 High

    Defined the core decay-protection mechanism: IGF2BP1 shields m6A-marked target mRNAs by sequestering them away from AGO2/RISC, resolving how stabilization is achieved.

    Evidence AGO2-RIP, miRNA depletion, m6A-dependent assays, xenografts across multiple targets

    PMID:29660014 PMID:30371874

    Open questions at the time
    • Structural basis of RISC competition not defined
    • Generality across all targets not established
  5. 2019 Medium

    Expanded the target repertoire to stem cell, fusion-oncogene, autophagy, and inflammatory programs, showing IGF2BP1 sustains leukemia stemness, stabilizes ETV6/RUNX1 transcripts, buffers autophagy genes, and supports NF-κB signaling.

    Evidence CLIP/PAR-CLIP, RIP, conditional knockout mice, double-mutant epistasis, and Co-IP across leukemia, intestinal, and macrophage systems

    PMID:26852652 PMID:31000200 PMID:31061170 PMID:31768017

    Open questions at the time
    • NF-κB association mechanism not resolved (RNA-dependent vs independent)
    • Autophagy gene binding mostly in silico/RIP without rescue for all targets
  6. 2020 Medium

    Revealed that an oncopeptide (RBRP) and a co-factor recruitment step (PABPC1) act as accessory modules strengthening IGF2BP1 m6A recognition and stabilization, and that IGF2BP1 has an RNA-independent function in activating SRC kinase.

    Evidence Co-IP, RNA pulldown, m6A recognition assays, RIP-seq/MeRIP-seq, RNA-binding-deficient mutants, in vivo models

    PMID:32245947 PMID:32876513 PMID:33391523

    Open questions at the time
    • RNA-independent SRC activation mechanism not structurally defined
    • Stoichiometry and generality of PABPC1 recruitment unknown
  7. 2021 High

    Showed IGF2BP1 abundance and activity are governed by ubiquitination and phosphorylation, defining FBXO45-driven activating ubiquitination and mTORC2/Src phospho-control of its translational repression function.

    Evidence Site-specific ubiquitination/phospho mutagenesis (K190/K450, Ser181, Tyr396), polysome analysis, transgenic and xenograft models

    PMID:33388443 PMID:34779401

    Open questions at the time
    • How non-degradative ubiquitination activates IGF2BP1 mechanistically unclear
    • Crosstalk between phospho- and ubiquitin marks not addressed
  8. 2021 Medium

    Established the RNA-binding KH domains as druggable: small molecules at the KH3-4 interface and KH1-2 Cys253 block target recognition, validating IGF2BP1 as a therapeutic target.

    Evidence Small molecule screening, direct binding to defined residues/domains, RNA-binding competition, in vivo xenografts (CuB reported 2022)

    PMID:34895045 PMID:36032766

    Open questions at the time
    • No co-crystal structure of inhibitor-bound complex reported
    • Selectivity over paralogs not established
  9. 2022 Medium

    Demonstrated IGF2BP1 function is shaped by phase separation and granule dynamics, with lncRNAs driving condensate formation that enhances target binding and stress/heat promoting m6A-dependent aggregation routed to proteasomal clearance.

    Evidence Phase separation assays, RNA-binding, granule imaging, m6A mutation, proteasome inhibition, PDX and HPV carcinogenesis models

    PMID:36214649 PMID:36288717

    Open questions at the time
    • Determinants of condensate composition not defined
    • Relationship between activating condensates and degradative granules unclear
  10. 2022 High

    Confirmed an in vivo developmental requirement: IGF2BP1 is needed for β-actin mRNA transport/anchoring and proper neocortical organization, anchoring its localization function in neurons genetically.

    Evidence IGF2BP1 knockout mice, endogenous β-actin-MS2 imaging, transport/anchoring and transcription-rate measurements

    PMID:36067310

    Open questions at the time
    • Molecular machinery of mRNA transport not fully resolved
    • Link to specific neuronal m6A marks not addressed
  11. 2023 High

    Broadened the regulatory and partner landscape: PRMT3 methylation (R452), TRIM29/USP10 ubiquitin balance, and partners RPS15, G3BP1, and the ETV6-RUNX1 fusion couple IGF2BP1 to drug resistance, immune evasion, metastasis, and leukemogenesis.

    Evidence CRISPR activation screens, site-specific mutagenesis, Co-IP/MS, m6A-RIP, RIP-seq/RNA-seq, in vivo tumor and pre-leukemic models

    PMID:36632454 PMID:37024475 PMID:37264021 PMID:37644505 PMID:37670323 PMID:38029830

    Open questions at the time
    • How distinct PTMs are integrated on a single IGF2BP1 molecule unknown
    • Whether RPS15/G3BP1 partnerships are constitutive or context-specific unresolved
  12. 2024 High

    Placed IGF2BP1 within a defined writer-reader axis and added palmitoylation as a control layer, showing it reads METTL16-deposited m6A on MYBL2 to drive HSPC cell-cycle progression and that ZDHHC1 palmitoylation tunes its output.

    Evidence Mettl16-deficient zebrafish with methyltransferase-dead rescue, cross-species m6A-RIP, palmitoylation site mutagenesis (C337), functional assays

    PMID:38605226 PMID:39069526

    Open questions at the time
    • Whether other writers feed IGF2BP1 in different tissues unknown
    • How palmitoylation alters IGF2BP1 localization/RNA selectivity not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • How IGF2BP1 selects between stabilizing versus destabilizing/translation-repressing fates for the same target (e.g. MYC) across cellular contexts remains unresolved.
  • Contradictory MYC outcomes reported in gastric cancer
  • No unifying rule linking PTM/condensate state to target fate
  • Context-dependent co-factor combinations not mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 9 GO:0045182 translation regulator activity 4 GO:0140098 catalytic activity, acting on RNA 3 GO:0140110 transcription regulator activity 2 GO:0140313 molecular sequestering activity 2
Localization
GO:0005829 cytosol 3 GO:0005634 nucleus 1
Pathway
R-HSA-392499 Metabolism of proteins 5 R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 3 R-HSA-8953854 Metabolism of RNA 3 R-HSA-168256 Immune System 2
Partners
FBXO45G3BP1PABPC1PRMT3RPS15TRIM29USP10ZDHHC1

Evidence

Reading pass · 35 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2012 IGF2BP1 promotes tumor cell migration velocity by inhibiting translation of MAPK4 mRNA, which prevents MK5 activation and HSP27 phosphorylation, thereby reducing G-actin sequestration and increasing F-actin polymerization. Simultaneously, IGF2BP1 stabilizes PTEN mRNA, enhancing PTEN expression and antagonizing PIP3 signaling to enforce RAC1-dependent cell polarization and directionality. RNA binding assays, knockdown/overexpression in tumor cell lines, cell migration assays, epistasis with MK5, RAC1, and HSP27 Genes & development High 22279049
2019 IGF2BP1 promotes SRF expression by impairing miRNA-directed decay of SRF mRNA in an m6A-dependent manner. IGF2BP1 associates with target mRNAs in RISC-free complexes and its deletion enhances mRNA association with AGO2, indicating IGF2BP1 antagonizes miRNA-mediated mRNA degradation by competing with RISC. Gene expression analysis, AGO2-RIP, miRNA depletion experiments, m6A-dependent assays, knockdown/overexpression in cancer cell lines and nude mouse xenografts Nucleic acids research High 29660014 30371874
2020 The oncopeptide RBRP (encoded by LINC00266-1) directly binds IGF2BP1 and strengthens its m6A recognition on target RNAs such as c-Myc mRNA, increasing mRNA stability and c-Myc expression to promote tumorigenesis. Co-immunoprecipitation, RNA pulldown, m6A recognition assays, mRNA stability assays, overexpression/knockdown in cancer cells Nature communications Medium 32245947
2021 IGF2BP1 recognizes m6A sites in the 3'UTR of PEG10 mRNA and recruits PABPC1 to enhance PEG10 mRNA stability, increasing PEG10 protein expression in endometrial cancer cells. RIP-seq, MeRIP-seq, RNA-seq, Co-immunoprecipitation and mass spectrometry to identify PABPC1 as interacting partner, mRNA stability assays Theranostics Medium 33391523
2022 A small molecule cucurbitacin B (CuB) directly targets IGF2BP1 at Cys253 in the KH1-2 domains, causing an allosteric effect that blocks IGF2BP1 recognition of m6A mRNA targets such as c-MYC. Chemical genetics, direct binding assays (Cys253 targeting), KH domain mutagenesis, m6A RNA binding assays, in vivo xenograft models ACS central science Medium 36032766
2023 PRMT3 methylates IGF2BP1 at R452, which is critical for IGF2BP1 function in stabilizing the mRNA of HEG1. PRMT3-mediated arginine methylation of IGF2BP1 drives oxaliplatin resistance in hepatocellular carcinoma. CRISPR/Cas9 activation library screen, transcriptomic profiling, site-specific mutagenesis at R452, mRNA stability assays, in vitro and in vivo functional validation Nature communications High 37024475
2021 FBXO45 E3 ubiquitin ligase promotes IGF2BP1 ubiquitination at Lys190 and Lys450, leading to IGF2BP1 activation and subsequent upregulation of PLK1 expression, driving cell proliferation and liver tumorigenesis. Co-immunoprecipitation, ubiquitination assays, site-specific mutagenesis (Lys190/Lys450), IGF2BP1 knockdown rescue experiments, transgenic mouse models eLife High 34779401
2023 TRIM29 E3 ubiquitin ligase interacts with IGF2BP1 and induces K48-linked ubiquitination at Lys440 and Lys450, leading to IGF2BP1 protein degradation. IGF2BP1 promotes PD-L1 mRNA stability in a 3'UTR and m6A-dependent manner, and TRIM29-mediated degradation of IGF2BP1 reduces PD-L1 expression to enhance antitumor T-cell immunity. Proteomics, co-immunoprecipitation, site-specific ubiquitination assays (K48-linked), mRNA stability assays, in vivo tumor models Cancer letters Medium 38029830
2023 USP10 deubiquitinase directly binds, deubiquitinates, and stabilizes IGF2BP1 protein. IGF2BP1 in turn recognizes m6A sites on CPT1A mRNA to enhance its stability, mediating breast cancer metastasis. Co-immunoprecipitation, deubiquitination assays, MeRIP-seq, mRNA stability assays, in vitro and in vivo metastasis models International journal of biological sciences Medium 36632454
2021 A small molecule inhibitor binds to a hydrophobic surface at the boundary of IGF2BP1 KH3 and KH4 domains and inhibits KRAS RNA binding, reducing KRAS mRNA and protein levels and downstream oncogenic signaling. Small molecule screening, direct binding assays to KH3/KH4 domain interface, RNA binding competition assays, wound healing and soft agar growth assays RNA biology Medium 34895045
2014 IGF2BP1 drives translation of cIAP1 mRNA in rhabdomyosarcoma cells, protecting them from TNF-α-mediated apoptosis. IGF2BP1 knockdown reduces cIAP1 levels and sensitizes cells to cell death. IGF2BP1 knockdown, cIAP1 protein and mRNA quantification, TNF-α-mediated apoptosis assays, in vivo tumor growth experiments with IAP antagonists Oncogene Medium 24704827
2017 IGF2BP1 overexpression in human adult erythroblasts causes fetal-like hemoglobin expression by reprogramming at the transcriptional level; mechanistically, IGF2BP1 reduces BCL11A protein expression via posttranscriptional mechanisms (mRNA stability and polysome analysis) to increase fetal hemoglobin. Erythroid-specific IGF2BP1 overexpression, hemoglobin quantification by HPLC, mRNA stability and polysome sedimentation assays for BCL11A Proceedings of the National Academy of Sciences of the United States of America Medium 28652347
2019 IGF2BP1 controls the cargo of melanoma-derived extracellular vesicles (EVs) to promote metastasis. IGF2BP1 knockdown did not alter EV size, number, or protein/RNA concentration, but altered EV mRNA, protein, and miRNA cargo, blocking pre-metastatic niche formation by inhibiting fibronectin deposition and CD45+ cell accumulation in lungs. In vivo metastasis models (two models), EV isolation and characterization, RNA-sequencing and proteomics of EVs, IGF2BP1 knockdown/overexpression Oncogene Medium 30936459
2020 IGF2BP1 maintains intestinal barrier function by directly binding occludin (Ocln) mRNA and stabilizing it, increasing occludin protein expression. Conditional knockout of IGF2BP1 in intestinal epithelial cells causes impaired tight junction function and colitis; ectopic occludin expression rescues barrier function in IGF2BP1-knockdown cells. Conditional knockout mouse (Villin CreERT2:Igf2bp1flox/flox), gut barrier assays, RIP demonstrating direct Ocln mRNA binding, mRNA stability assays, occludin rescue experiments The Journal of biological chemistry High 32385106
2019 IGF2BP1 directly binds and stabilizes ETV6/RUNX1 fusion mRNA in t(12;21)-positive acute lymphoblastic leukemia, as shown by RIP enrichment and the reduction of ETV6/RUNX1 mRNA upon IGF2BP1 knockdown. RNA immunoprecipitation (RIP), IGF2BP1 knockdown, quantification of ETV6/RUNX1 mRNA in cell lines and primary patient samples Blood cells, molecules & diseases Medium 26852652
2019 IGF2BP1 maintains leukemia stem cell properties by stabilizing HOXB4, MYB, and ALDH1A1 mRNAs, as demonstrated by CLIP and PAR-CLIP techniques. Chemical or genetic inhibition of IGF2BP1 decreases tumorigenicity, promotes differentiation, and sensitizes leukemia cells to chemotherapy. CLIP, PAR-CLIP, gain- and loss-of-function systems, tumor-initiating potential assays Leukemia Medium 31768017
2020 IGF2BP1 promotes SRC kinase activation through a protein-ligand-induced, RNA-independent mechanism, and separately enhances ERK2 expression in an RNA-binding-dependent manner, connecting SRC/MAPK signaling to promote invasive growth in ovarian cancer cells. Protein interaction studies, SRC kinase activation assays, RNA-binding-deficient mutants, 3D invasion cultures, intraperitoneal mouse models, SRC/MEK inhibitor rescue experiments RNA biology Medium 32876513
2019 IGF2BP1 binds Lnc-THOR RNA; disruption of Lnc-THOR–IGF2BP1 association (by triptonide or Lnc-THOR/IGF2BP1 CRISPR knockout) depletes IGF2BP1 mRNA targets (Myc, IGF2, Gli1) and inhibits NPC cell growth, establishing that Lnc-THOR stabilizes IGF2BP1-dependent target mRNAs. Small molecule disruption, CRISPR/Cas9 knockout of Lnc-THOR and IGF2BP1, target mRNA quantification, in vivo xenograft models Cancer letters Medium 30503558
2021 mTORC2 phosphorylates IGF2BP1 at Ser181; prevention of this phosphorylation enhances translation and destabilization of c-myc mRNA. Src kinase phosphorylates IGF2BP1 at Tyr396; prevention of Tyr396 phosphorylation causes accumulation of translationally silent IGF2BP1-sequestered mRNA in cytoplasmic granules. mTORC2 and Src kinase inhibition, phospho-site mutagenesis (Ser181, Tyr396), reporter assays with CRD sequence, polysome analysis, xenograft models Cellular signalling Medium 33388443
2019 IGF2BP1 directly binds MAP1LC3B, ATG3, and ATG5 transcripts (autophagy gene mRNAs), as demonstrated by in silico and biochemical analyses. Intestinal epithelial Imp1 deletion leads to upregulation of Atg5 and increased autophagy flux, and double knockout of Imp1 and Atg7 increases sensitivity to colonic injury, establishing a compensatory relationship between IMP1/IGF2BP1 and autophagy. Conditional knockout mice, RNA-IP, in silico binding analysis, DSS colitis models, autophagy flux assays, double-mutant epistasis EMBO reports Medium 31061170
2022 IGF2BP1 knockout mice display disorganized neocortical development with loss of cortical marginal cell density and fewer mitotically active cells. In IGF2BP1-null neurons, β-actin mRNA shows increased transcription rates and total protein content but decreased transport and anchoring, demonstrating IGF2BP1 is required for proper β-actin mRNA localization and transport in neurons. IGF2BP1 knockout mice, BrdU labeling, endogenously tagged β-actin-MS2 mRNA imaging, mRNA transport and anchoring measurements, transcription rate analysis Proceedings of the National Academy of Sciences of the United States of America High 36067310
2015 Igf2bp1 knockdown in zebrafish reduces retinal ganglion cell (RGC) axonal outgrowth and tectal coverage. RGC-specific expression of a phosphomimetic Igf2bp1 reduces axonal projection density without affecting RGC survival, demonstrating Igf2bp1 is required for axon outgrowth in vivo and that its phosphorylation state modulates this function. Morpholino knockdown and phosphomimetic rescue in zebrafish, timelapse imaging of RGC axon outgrowth, photoconvertible fluorescent protein reporter under β-actin 3'UTR PloS one Medium 26325373
2023 RPS15 interacts with the KH domain of IGF2BP1, and this complex recognizes and directly binds the 3'UTR of MKK6 and MAPK14 mRNAs in an m6A-dependent manner to promote translation of core p38 MAPK pathway proteins and drive ESCC metastasis. CRISPR SAM library screen, Co-IP of RPS15-IGF2BP1, m6A-dependent RIP for MKK6/MAPK14 mRNAs, targeted drug screening, in vitro and in vivo functional assays Signal transduction and targeted therapy Medium 37264021
2019 IGF2BP1 promotes LPS-induced NFκB signaling in human macrophages and monocytes. Co-immunoprecipitation showed IGF2BP1 associates with the p65-p52 NFκB complex in nuclei of LPS-treated cells; IGF2BP1 knockdown/knockout inhibits p65-p52 nuclear translocation and NFκB transcriptional activation. Co-immunoprecipitation of IGF2BP1 with NFκB p65-p52, nuclear fractionation, shRNA knockdown and CRISPR/Cas9 KO, cytokine ELISA Biochemical and biophysical research communications Medium 31000200
2022 MNX1-AS1 lncRNA binds IGF2BP1 and drives its phase separation, which increases IGF2BP1 interaction with the 3'UTR of c-Myc and E2F1 mRNAs to promote their stability, creating a c-Myc/MNX1-AS1/IGF2BP1 positive feedback loop driving cell-cycle progression. RNA-protein binding assays, phase separation assays, 3'UTR interaction studies, cell cycle analysis, patient-derived xenograft model Cancer research Medium 36214649
2023 MKRN3 interacts with IGF2BP1 (identified by proteomics), and IGF2BP1 in turn interacts with polyadenylate-binding protein family members, positioning IGF2BP1 as a target of MKRN3-mediated regulation of hypothalamic puberty-related gene expression. Proteomics interactome analysis, co-immunoprecipitation, Mkrn3 knockout mouse model JCI insight Low 37092553
2023 IGF2BP1 directly binds and stabilizes INHBA mRNA; knockdown of IGF2BP1 reduces INHBA expression and attenuates Smad2/3 signaling to suppress ESCC cell invasion and migration. IGF2BP1 also interacts with G3BP1, and G3BP1 knockdown similarly downregulates INHBA-Smad2/3 signaling. RIP-seq, mass spectrometry for interacting proteins (identifying G3BP1), gene-specific m6A PCR, RNA stability assays, BTYNB inhibitor treatment Experimental hematology & oncology Medium 37644505
2024 ZDHHC1 palmitoylates IGF2BP1 at C337 (S-palmitoylation), which results in downregulated expression of LIPG mRNA via m6A modification, suppressing colorectal cancer cell growth. Palmitoylation assays, site-specific mutagenesis (C337), m6A modification analysis, mRNA stability assays, in vitro and in vivo functional studies Cancer gene therapy Medium 39069526
2023 IGF2BP1 directly binds and governs expression of SEMA3A and SHMT2 in neuroblastoma cells, modulating their protein levels in small extracellular vesicles (EVs) to regulate pro-metastatic microenvironment formation at potential metastatic organs. Unbiased proteomics of EVs, direct binding assays, knockdown/overexpression in immunocompetent mouse NB models, EV isolation and characterization Oncogene Medium 36973517
2017 IGF2BP1 is identified as a novel binding partner of p38 MAPK by co-immunoprecipitation followed by mass spectrometry. Co-immunoprecipitation, mass spectrometry, in silico domain interaction analysis Molecular and cellular biochemistry Low 28497370
2023 IGF2BP1 stabilizes c-MYC mRNA via m6A-dependent binding in gastric cancer cells, promoting aerobic glycolysis and cancer progression. However, a separate study in gastric cancer found IGF2BP1 promotes degradation and reduces translation efficiency of MYC mRNA in an m6A-dependent manner, suggesting a cell-context-dependent switch in IGF2BP1's regulation of MYC. RIP, MeRIP, mRNA stability assays, polysome profiling, gain/loss of function in gastric cancer cells Experimental cell research / Cancer science Low 35489385 38115228
2022 IGF2BP1 stabilizes EZH2 mRNA in an m6A-dependent manner in neuroendocrine tumor cells, enhancing EZH2 protein levels which then trimethylates H3K27 to silence cell cycle arrest genes and drive proliferation. mRNA stability assays, m6A-dependent RIP, IGF2BP1 inhibitor (BTYNB), cell cycle analysis, H3K27me3 ChIP Cancers Medium 35565249
2022 Heat treatment promotes IGF2BP1 aggregation specifically in the presence of m6A-modified HPV E7 mRNA, forming heat-induced m6A E7 mRNA-IGF2BP1 granules that are resolved by the ubiquitin-proteasome system, downregulating E7 mRNA and protein. Heat treatment assays, m6A mutation experiments, granule imaging, proteasome inhibition assays, in vitro and in vivo HPV carcinogenesis models Cell reports Medium 36288717
2024 In zebrafish, Igf2bp1 acts as a reader of METTL16-mediated m6A modifications on mybl2b mRNA (cell-cycle transcription factor); Mettl16 deficiency destabilizes mybl2b mRNA due to lost Igf2bp1 binding, causing G1/S arrest in embryonic hematopoietic stem and progenitor cells. The METTL16-m6A-MYBL2-IGF2BP1 axis is conserved in humans. Single-cell RNA-seq cross-species, Mettl16-deficient zebrafish, methyltransferase-dead rescue, m6A-RIP for mybl2b, in vivo HSPC proliferation assays, human cell validation The EMBO journal High 38605226
2023 IGF2BP1 synergizes with ETV6-RUNX1 fusion protein in B-ALL by binding and stabilizing the ETV6::RUNX1 fusion transcript, creating a positive feedback loop that constitutively dysregulates TNFα/NFκB and PI3K-Akt oncogenic pathways; co-expression in mouse bone marrow causes pre-leukemic hypercellularity and splenomegaly. RIP-seq after IGF2BP1 pulldown, RNA-seq after IGF2BP1 KO, bone marrow transplant mouse model with retroviral co-expression, patient sample validation Journal of experimental & clinical cancer research High 37670323

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic acids research 307 30371874
2018 Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. Journal of hematology & oncology 229 29954406
2020 An oncopeptide regulates m6A recognition by the m6A reader IGF2BP1 and tumorigenesis. Nature communications 225 32245947
2021 IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression. Theranostics 175 33391523
2022 Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment. ACS central science 133 36032766
2012 IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling. Genes & development 127 22279049
2019 RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1. Leukemia 118 31768017
2018 IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic acids research 115 29660014
2023 HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway. Journal of experimental & clinical cancer research : CR 82 36747239
2023 PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nature communications 80 37024475
2018 Triptonide inhibits human nasopharyngeal carcinoma cell growth via disrupting Lnc-RNA THOR-IGF2BP1 signaling. Cancer letters 80 30503558
2022 MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc-Mediated Cell-Cycle Progression and Proliferation in Lung Cancer. Cancer research 77 36214649
2022 Downregulation of METTL14 improves postmenopausal osteoporosis via IGF2BP1 dependent posttranscriptional silencing of SMAD1. Cell death & disease 77 36319624
2023 Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner. International journal of biological sciences 69 36632454
2021 Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells. RNA biology 61 34895045
2021 Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation. eLife 60 34779401
2015 miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma. Cell proliferation 60 26332146
2023 TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer. Cancer letters 57 38029830
2019 Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis. Oncogene 57 30936459
2001 C-MYC and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in benign and malignant mesenchymal tumors. International journal of cancer 56 11745432
2015 miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1. Molecular cancer 55 25889892
2020 The mRNA-binding protein IGF2BP1 maintains intestinal barrier function by up-regulating occludin expression. The Journal of biological chemistry 49 32385106
2016 MicroRNA-98-5p Inhibits Cell Proliferation and Induces Cell Apoptosis in Hepatocellular Carcinoma via Targeting IGF2BP1. Oncology research 49 28244848
2012 IGF2BP1: a post-transcriptional "driver" of tumor cell migration. Cell adhesion & migration 49 22983196
2021 IGF2BP1 Promotes the Liver Cancer Stem Cell Phenotype by Regulating MGAT5 mRNA Stability by m6A RNA Methylation. Stem cells and development 47 34514861
2020 Emergence of carbapenem-resistant and colistin-susceptible Enterobacter cloacae complex co-harboring blaIMP-1 and mcr-9 in Japan. BMC infectious diseases 47 32299378
2022 MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modification. Cell & bioscience 46 35346372
2014 IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene 45 24704827
2023 Inhibition of IGF2BP1 attenuates renal injury and inflammation by alleviating m6A modifications and E2F1/MIF pathway. International journal of biological sciences 44 36632449
2017 IGF2BP1 overexpression causes fetal-like hemoglobin expression patterns in cultured human adult erythroblasts. Proceedings of the National Academy of Sciences of the United States of America 44 28652347
2023 RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m6A modification. Signal transduction and targeted therapy 42 37264021
2020 IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 40 32719445
2020 LIN28B-AS1-IGF2BP1 binding promotes hepatocellular carcinoma cell progression. Cell death & disease 38 32917856
2022 RNA binding protein IGF2BP1 meditates oxidative stress-induced granulosa cell dysfunction by regulating MDM2 mRNA stability in an m6A-dependent manner. Redox biology 36 36182806
2021 IGF2BP1, a Conserved Regulator of RNA Turnover in Cancer. Frontiers in molecular biosciences 36 33829040
2020 miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma. Molecular carcinogenesis 36 33052627
2018 IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth. Biochemical and biophysical research communications 36 29753746
2020 IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. RNA biology 35 32876513
2017 MicroRNA-124-3p inhibits cell growth and metastasis in cervical cancer by targeting IGF2BP1. Experimental and therapeutic medicine 35 29399123
2011 Structural and kinetic studies on metallo-β-lactamase IMP-1. Biochemistry 35 21928807
2023 RUNX1-IT1 favors breast cancer carcinogenesis through regulation of IGF2BP1/GPX4 axis. Discover oncology 33 37036576
2010 IGF2BP1, IGF2BP2 and IGF2BP3 genotype, haplotype and genetic model studies in metabolic syndrome traits and diabetes. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 31 20627640
2023 IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression. Cancer letters 30 36736530
2022 m6A modification confers thermal vulnerability to HPV E7 oncotranscripts via reverse regulation of its reader protein IGF2BP1 upon heat stress. Cell reports 30 36288717
2021 METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC. Biochemical and biophysical research communications 30 33582561
2023 Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells. Experimental hematology & oncology 28 37644505
2020 microRNA-670 modulates Igf2bp1 expression to regulate RNA methylation in parthenogenetic mouse embryonic development. Scientific reports 28 32179813
2017 SOX12 upregulation is associated with metastasis of hepatocellular carcinoma and increases CDK4 and IGF2BP1 expression. European review for medical and pharmacological sciences 28 28975985
2025 CircRNF13 enhances IGF2BP1 phase separation-mediated ITGB1 mRNA stabilization in an m6A-dependent manner to promote oral cancer cisplatin chemoresistance. Molecular cancer 27 39891203
2015 ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia. Blood cells, molecules & diseases 26 26852652
2019 Posttranscriptional regulation of colonic epithelial repair by RNA binding protein IMP1/IGF2BP1. EMBO reports 25 31061170
2019 LncRNA THOR promotes tongue squamous cell carcinomas by stabilizing IGF2BP1 downstream targets. Biochimie 25 31220513
2017 Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation. PloS one 25 28486549
2023 IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis. Oncogene 24 36973517
2022 N6-methyladenosine (m6A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner. Experimental cell research 24 35489385
2022 IGF2BP1-regulated expression of ERRα is involved in metabolic reprogramming of chemotherapy resistant osteosarcoma cells. Journal of translational medicine 24 35918761
2019 IGF2BP1 promotes LPS-induced NFκB activation and pro-inflammatory cytokines production in human macrophages and monocytes. Biochemical and biophysical research communications 24 31000200
2023 BTYNB, an inhibitor of RNA binding protein IGF2BP1 reduces proliferation and induces differentiation of leukemic cancer cells. Saudi journal of biological sciences 22 36816728
2023 MKRN3 inhibits puberty onset via interaction with IGF2BP1 and regulation of hypothalamic plasticity. JCI insight 22 37092553
2023 FGF19/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 22 38048735
2018 Expression of microRNA-150 and its Target Gene IGF2BP1 in Human Osteosarcoma and their Clinical Implications. Pathology oncology research : POR 22 30220021
2023 METTL3 potentiates osteogenic differentiation of bone marrow mesenchymal stem cells via IGF2BP1/m6A/RUNX2. Oral diseases 21 36705430
2023 Development of a specific and potent IGF2BP1 inhibitor: A promising therapeutic agent for IGF2BP1-expressing cancers. European journal of medicinal chemistry 21 37976707
2020 Zipcode Binding Protein 1 (ZBP1; IGF2BP1): A Model for Sequence-Specific RNA Regulation. Cold Spring Harbor symposia on quantitative biology 21 32086331
2024 A Mettl16/m6A/mybl2b/Igf2bp1 axis ensures cell cycle progression of embryonic hematopoietic stem and progenitor cells. The EMBO journal 20 38605226
2024 ZDHHC1 downregulates LIPG and inhibits colorectal cancer growth via IGF2BP1 Palmitoylation. Cancer gene therapy 20 39069526
2022 Silencing of IGF2BP1 restrains ox-LDL-induced lipid accumulation and inflammation by reducing RUNX1 expression and promoting autophagy in macrophages. Journal of biochemical and molecular toxicology 20 35179253
2022 Tagged actin mRNA dysregulation in IGF2BP1[Formula: see text] mice. Proceedings of the National Academy of Sciences of the United States of America 20 36067310
2021 Long noncoding RNA NBAT1 suppresses hepatocellular carcinoma progression via competitively associating with IGF2BP1 and decreasing c-Myc expression. Human cell 20 33387362
2014 IMP-1 encoded by a novel Tn402-like class 1 integron in clinical Achromobacter xylosoxidans, China. Scientific reports 20 25428613
2023 N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer. Apoptosis : an international journal on programmed cell death 19 37848671
2022 TFAP4 Activates IGF2BP1 and Promotes Progression of Non-Small Cell Lung Cancer by Stabilizing TK1 Expression through m6A Modification. Molecular cancer research : MCR 19 36074102
2021 circBICD2 targets miR-149-5p/IGF2BP1 axis to regulate oral squamous cell carcinoma progression. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 19 33382158
2021 Designing multiepitope-based vaccine against Eimeria from immune mapped protein 1 (IMP-1) antigen using immunoinformatic approach. Scientific reports 19 34521964
2019 microRNA-4500 inhibits human glioma cell progression by targeting IGF2BP1. Biochemical and biophysical research communications 18 31000197
2025 IGF2BP1/AIFM2 axis regulates ferroptosis and glycolysis to drive hepatocellular carcinoma progression. Cellular signalling 17 39971223
2023 N6-methyladenosine (m6A) reader IGF2BP1 facilitates clear-cell renal cell carcinoma aerobic glycolysis. PeerJ 17 36691477
2022 Computational modelling of potential Zn-sensitive non-β-lactam inhibitors of imipenemase-1 (IMP-1). Journal of biomolecular structure & dynamics 17 36476097
2021 mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival. Cellular signalling 17 33388443
2023 Silencing of circCRIM1 Drives IGF2BP1-Mediated NSCLC Immune Evasion. Cells 16 36672208
2023 RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia. Journal of experimental & clinical cancer research : CR 16 37670323
2015 The RNA Binding Protein Igf2bp1 Is Required for Zebrafish RGC Axon Outgrowth In Vivo. PloS one 16 26325373
2023 Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer. Journal of medicinal chemistry 15 37681508
2023 Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC. Cancer science 15 38115228
2022 m6A-binding protein IGF2BP1 promotes the malignant phenotypes of lung adenocarcinoma. Frontiers in oncology 15 36249006
2021 Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents. Frontiers in oncology 15 33796454
2019 Molecular and epidemiological analysis of IMP-1 metallo-β-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 15 30611637
2022 Structural insights into the substrate specificity of IMP-6 and IMP-1 metallo-β-lactamases. Journal of biochemistry 14 36174533
2021 The InDel variants of sheep IGF2BP1 gene are associated with growth traits. Animal biotechnology 14 34255980
2024 Exosomes containing circSCP2 in colorectal cancer promote metastasis via sponging miR-92a-1-5p and interacting with PTBP1 to stabilize IGF2BP1. Biology direct 13 39702234
2023 CDCA4 interacts with IGF2BP1 to regulate lung adenocarcinoma proliferation via the PI3K/AKT pathway. Thoracic cancer 13 36737405
2023 IGF2BP1 facilitates non-small cell lung cancer progression by regulating the KIF2A-mediated Wnt/β-catenin pathway. Functional & integrative genomics 13 38102458
2022 IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2. Cancers 13 35565249
2022 IMP1/IGF2BP1 in human colorectal cancer extracellular vesicles. American journal of physiology. Gastrointestinal and liver physiology 13 36194131
2022 Oncofetal protein IGF2BP1 regulates IQGAP3 expression to maintain stem cell potential in cancer. iScience 13 36217548
2017 IGF2BP1: a novel binding protein of p38 MAPK. Molecular and cellular biochemistry 13 28497370
2023 A novel feedback regulated loop of circRRM2-IGF2BP1-MYC promotes breast cancer metastasis. Cancer cell international 12 36966311
2023 The m6A reader IGF2BP1 manipulates BUB1B expression to affect malignant behaviors, stem cell properties, and immune resistance of non-small-cell lung cancer stem cells. Cytotechnology 12 37841956
2024 METTL3 promotes the progression of osteosarcoma through the N6-methyladenosine modification of MCAM via IGF2BP1. Biology direct 11 38849910
2024 Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 39488785

Missed literature

Know a paper Affinage missed for IGF2BP1? Flag it for the maintainers and the community.

No submissions yet.